tiprankstipranks
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
US Market
GALT
Galectin Therapeutics
RESEARCH TOOLSreports
Want to see GALT full AI Analyst Report?

Galectin Therapeutics (GALT) Income Statement

670 Followers

Galectin Therapeutics Income Statement

Last quarter (Q4 2025), Galectin Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Galectin Therapeutics's net income was $-5.50M. See Galectin Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Dec 23Dec 22Mar 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ -37.00K$ -33.00K$ -32.00K$ -41.00K
Operating Expenses
$ 20.09M$ 42.40M$ 38.04M$ 38.32M$ 30.14M
Depreciation and Amortization
$ 53.00K$ 37.00K$ 33.00K$ 32.00K$ 41.00K
EBITDA
$ -23.45M$ -41.47M$ -38.24M$ -37.71M$ -30.00M
Operating Income
$ -20.09M$ -42.43M$ -38.07M$ -38.35M$ -30.18M
Other Income/Expenses
$ -10.75M$ -4.61M$ -2.99M$ -424.00K$ -348.00K
Pretax Income
$ -30.84M$ -47.05M$ -41.07M$ -38.78M$ -30.53M
Net Income
$ -30.84M$ -47.05M$ -41.07M$ -38.78M$ -30.53M
Per Share Metrics
Basic EPS
$ -0.48$ -0.76$ -0.74$ -0.65$ -0.52
Diluted EPS
$ -0.48$ -0.76$ -0.74$ -0.65$ -0.52
Weighted Average Shares Outstanding
 63.90M 62.31M 60.16M 59.39M 58.53M
Weighted Average Shares Outstanding (Diluted)
 63.90M 62.31M 60.16M 59.39M 58.53M
Currency in USD

Galectin Therapeutics Earnings and Revenue History